Edition:
United Kingdom

Veracyte Inc (VCYT.OQ)

VCYT.OQ on NASDAQ Stock Exchange Global Market

6.44USD
15 Dec 2017
Change (% chg)

$0.14 (+2.30%)
Prev Close
$6.30
Open
$6.28
Day's High
$6.56
Day's Low
$6.28
Volume
784,633
Avg. Vol
50,542
52-wk High
$9.78
52-wk Low
$5.75

Latest Key Developments (Source: Significant Developments)

Veracyte posts Q3 loss per share $0.21
Monday, 6 Nov 2017 

Nov 6 (Reuters) - Veracyte Inc :Veracyte announces third quarter 2017 financial results.Q3 loss per share $0.21.Q3 revenue $17.5 million versus I/B/E/S view $19.5 million.Q3 earnings per share view $-0.23 -- Thomson Reuters I/B/E/S.Sees FY 2017 revenue $71 million to $72 million.Veracyte Inc - ‍narrowing range of its annual cash burn guidance to $25 to $26 million​.  Full Article

Veracyte announces launch of Envisia Genomic Classifier
Tuesday, 25 Oct 2016 

Veracyte Inc : Veracyte Inc says announces launch of envisia genomic classifier for improved diagnosis of idiopathic pulmonary fibrosis .Veracyte Inc says will begin making envisia genomic classifier available to a limited number of institutions in December.  Full Article

Veracyte sees 2016 revenue $59 million to $63 million
Wednesday, 3 Aug 2016 

Veracyte Inc : Q2 loss per share $0.40 . Sees FY 2016 revenue $59 million to $63 million . Veracyte announces second quarter 2016 financial results . Q2 earnings per share view $-0.33 -- Thomson Reuters I/B/E/S . Q2 revenue $14.7 million versus i/b/e/s view $14.8 million .Fy2016 earnings per share view $-1.29, revenue view $61.5 million -- Thomson Reuters I/B/E/S.  Full Article

Veracyte CFO Shelly Guyer resigns
Monday, 13 Jun 2016 

Veracyte Inc : Veracyte announces resignation of its chief financial officer . Says CFO Shelly Guyer resigned .Initiated a national search for a new chief financial officer.  Full Article

Reimbursement cuts on lab tests pressure US lab firm shares

Nov 20 A federal agency on Friday rolled out deep cuts to reimbursement rates for some lab tests under Medicare, a move that could save the government as much as $3 billion over five years, but hurt margins of U.S. laboratory companies.